We were at DIA Europe 2023 in Basel discussing means to accelerate cell and gene therapy development.
While technical progress leads to a wide range of opportunities, the transformation of the wider ecosystem still requires a lot of concerted effort from all parties.

Tigen welcomes Michel Orsinger to the board of directors. As a global leader, Michel will support Tigen’s growth through his extensive healthcare and leadership experience.

Tigen exercises first option from the T Cell Program at the Centre hospitalier universitaire vaudois (CHUV) on behalf of the Ludwig Institute for Cancer Research for the development of a Neoantigen-specific Tumor Infiltrating Lymphocytes product (NeoTIL).

Join us in welcoming Simon Eade as Chief Business Officer.

Emily Whitehead Foundation, Bruce Levin and Stephan Grupp visiting the Tigen lab in Lausanne and discussing what's next in Cell & Gene Therapies.

Why we need a revolution for personalized cell therapies.

Join us in welcoming Simon Chaplin as Chief Financial Officer.

Dorothea Ledergerber discussing the future of cell & gene therapies manufacturing at the Advanced Therapies get-together in London.

Join us in welcoming Therese Choquette (Vallerskog) to the Tigen team as Head of Analytical Sciences.